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Abstract
The cylindromatosis tumor suppressor (CYLD) is a deubiquitinating enzyme that has been implicated in various aspects of
adaptive and innate immune responses. Nevertheless, the role of CYLD in the function of specific types of immune cells
remains elusive. In this report we have used conditional gene targeting in mice to address the role of the deubiquitinating
activity of CYLD in the myelomonocytic lineage. Truncation of the deubiquitinating domain of CYLD specifically in
myelomonocytic cells impaired the development of lethal LPS-induced endotoxic shock and the accumulation of
thioglycollate-elicited peritoneal macrophages. Our data establish CYLD as a regulator of monocyte-macrophage activation
in response to inflammatory stimuli and identify it as a potential target for therapeutic intervention in relevant inflammatory
disorders in humans.
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Introduction
Cyld was identified as the predisposition gene for the tumor
syndrome of familial cylindromatosis. It mediates the suppression
of the NF-kB, JNK, p38 and Wnt pathways in a manner that
depends on its deubiquitinating activity (reviewed in [1]). The use
of mouse models of CYLD deficiency has implicated the protein in
the regulation of multiple physiological processes including T cell
development and activation, B cell homeostasis and function,
osteoclastogenesis and spermatogenesis (Reviewed in [2]). More-
over, CYLD downregulation sensitizes mice to various patholog-
ical conditions that include chemically induced skin tumor
formation as well as colitis-associated cancer [3–4]. Interestingly,
in all these cases a broad range of CYLD-targeted proteins could
be recognized, establishing CYLD as a multi-tasking deubiquiti-
nating enzyme implicated in the fine tuning of many develop-
mental and physiological processes.
A number of studies have provided compelling evidence for the
implication of CYLD in various aspects of innate immunity. More
specifically, it has been shown that CYLD constitutes a key
negative regulator of NF-kB and JNK in macrophages from Cyld
null mice that have been treated with CD40 or ligands against
TLR4 and TLR2 [4]. Another study showed that Cyld-deficient
mice were more resistant to lethal pulmonary infection caused by
Streptococcal pneumoniae. This was attributed to enhanced p38
activation and subsequent elevated expression of PAI-1 [5,6].
However, a third study did not recognize any difference in the
activity of NF-kB or MAPKs in macrophages following treatment
with TNF or TLR stimulation, using an independently derived
mouse model of Cyld deficiency [7]. In all the aforementioned
studies mice bearing obligatory null alleles were used making it
impossible to discern the cell-specific contribution of CYLD to the
observed phenotype [8].
In the present study we employed a conditional gene targeting
approach to introduce a cell-specific deubiquitinating-domain-
truncating mutation in the Cyld locus (Cyld
D9) and investigate a
plausible implication of CYLD in the development and function of
the myelomonocytic lineage. In accordance with previous studies
no obvious hematopoietic defects were observed. However, Cyld
D9
mice exhibited increased resistance to LPS induced endotoxic
shock. Moreover, in an in vivo model of induced peritonitis CYLD-
deficient macrophages failed to accumulate to the inflammatory
site. Overall, our data demonstrate that Cyld is dispensable for
hematopoiesis but unravel a cell intrinsic function of Cyld in
monocyte-macrophage response to inflammatory stimuli.
Results and Discussion
Generation and characterization of M-Cyld
D9 mice
The generation of mice with loxP sites flanking the exon 9 of the
Cyld locus (Cyld
flx9/flx9), has been described elsewhere [9]. By
crossing these mice to LysMcre transgenic mice we aimed to render
murine CYLD catalytically inactive in myelomonocytic cells, by
truncating its catalytic domain through Cre-mediated excision of
exon 9[9,10]. In accordance with the expression of the Cre
recombinase in myelomonocytic cells in LysMCre-Cyld
flx9/flx9 mice
(termed M-Cyld
D9 mice from this point onwards), the effective
excision of Cyld exon 9 was readily evident both in bone marrow
purified progenitor cells (Fig. 1A) and in splenic sorted
macrophages (Fig. 1B). Finally, immunoblotting with an anti-
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CYLD protein in M-Cyld
D9 bone marrow derived macrophages
(BMDMs, Fig. 1C). M-Cyld
D9 mice were viable and normal in
appearance. Since CYLD has been implicated in T cell
development [7,11] the hematopoietic development in M-Cyld
D9
mice was evaluated. No gross hematopoietic defect was detected
by flow cytometric analysis of the combined expression of Ly6C
and CD31 surface markers both in steady state conditions and
after thioglycollate-induced peritonitis that was adopted in order to
evaluate the hematopoietic capacity of M-Cyld
D9 mice under stress
(Fig. 2A). Interestingly, the higher numbers of splenic macrophag-
es in M-Cyld
D9 mice (Figure 2B) further support the fact that there
is not a hematopoietic defect.
M-Cyld
D9 mice are less susceptible to LPS-induced
endotoxic shock
Macrophages constitute a central player of the innate immune
response. The NF-kB pathway has been implicated in many
aspects of macrophage activation and function. p50/NF-kB1
2/2
mice show increased susceptibility to LPS-induced endotoxic
shock due to decreased IL-10 production [12]. Interestingly,
increased ubiquitination and degradation of p50 was observed in
Bcl3
2/2 macrophages leading to the abolishment of LPS tolerance
and the increased susceptibility of mice that lack BCL3 to LPS-
induced shock [13]. Since CYLD has been shown to be a negative
regulator of the NF-kB pathway in various cell types, its ability to
modulate the activity of NF-kBi nCyld
D9 BMDMs was evaluated
by EMSA. As expected, the basal NF-kB activity was significantly
elevated in Cyld
D9 BMDMs in comparison to control BMDMs
(Fig. 3). This finding prompted an investigation into the response
of M-Cyld
D9 mice to LPS. M-Cyld
D9 and control mice were injected
with 32 mg/kg of bacterial LPS. While only 20% of the control
mice survived, the survival rate of M-Cyld
D9 mice reached 80%.
Interestingly, M-Cyld
D9 mice not only showed increased resistance
but also increased endurance since they died later than the control
animals (Fig. 4A). Moreover, the levels of secreted TNFa following
LPS treatment were not higher in M-Cyld
D9 BMDMs compared to
control BMDMs. Instead, there was a tendency for lower secretion
of TNFa by M-Cyld
D9 BMDMs following LPS treatment, even
though this was not statistically significant (Figure 4B). The
response of M-Cyld
D9 mice to LPS-induced endotoxemia was
surprising, given the hyperactivation of NF-kBi nM-Cyld
D9
BMDMs. A possible explanation for the observed phenotype
could be the adoption of alternative activation by M-Cyld
D9
macrophages, which leads to the secretion of anti-inflammatory
cytokines such as IL-10 [14]. Interestingly, NF-kB can exert an
anti-inflammatory role besides its well known proinflammatory
activity, which mediates the resolution of inflammation [15].
Moreover, it has been shown that conditional inactivation of
IKK2 in myelomonocytic cells and subsequent endotoxin
challenge of the resultant mice leads to increased endotoxin
induced mortality and increased levels of IL-1b. Prolonged
pharmacological inhibition of IKKb, which interferes with NF-
kB activation in the whole animal, also increased LPS-induced
mortality and plasma IL-1b[16]. Therefore a plausible scenario
would be that in M-Cyld
D9 mice the aberrant activation of NF-kB
leads to suppression of IL1b generation as well as of the secretion
of other inflammatory cytokines. Indeed, our findings are
consistent with the resistance of Cyld null mice to lethality
following acute lung injury by Streptococcus pneumoniae [6] and
suggest that the lack of functional CYLD in macrophages may
contribute to the increased survival of Cyld null mice. The
availability of M-Cyld
D9 mice will permit the experimental
evaluation of this hypothesis in order to pinpoint the cellular
basis of Cyld-deficient mice resistance to lethal lung injury by
Streptococcus pneumonia.
M-Cyld
D9 mice show decreased accumulation of
thioglycollate-elicited peritoneal macrophages
In order to investigate further the implication of Cyld in the
inflammatory response we employed an in vivo model of
macrophage recruitment by inducing chemically aseptic peritoni-
Figure 1. Generation and characterization of mice with
inactivation of CYLD specifically in myelomonocytic cells. Cyld
recombination is detected by genomic PCR in Lin
2 precursor cells
isolated from bone marrow (A) as well as in mature macrophages sorted
from spleen (B). C) Immunoblotting of whole cell extracts from BMDMs
isolated from control and M-Cyld
D9 mice with anti-CYLD and anti-ACTIN
antibodies.
doi:10.1371/journal.pone.0016397.g001
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extensively used inflammatory stimulus that induces the recruit-
ment of neutrophils and macrophages to the peritoneal cavity
[17]. In this model, neutrophil number reaches a maximum at
8 hours, while macrophages migrate with a slow time course,
reaching a maximum at 72 hours and remaining at this level for at
Figure 2. Normal hematopoietic development in M-Cyld
D9 mice. A) Enumeration of the indicated hematopoietic lineage cells (lower panel) by
flow cytometric analysis of bone marrow cells for the expression of Ly6c and CD31 surface markers at steady state conditions (upper left panel) and
after 72 h of thioglycollate treatment (upper right panel). In the first case 5 control and 3 M-Cyld
D9 mice were evaluated whereas in the second case 7
control and 5 M-Cyld
D9 mice were evaluated. B) Monocyte lineage populations in spleen. Enumeration of cells in the spleen that were collected from
control (M-Cyld
+) and mutant (M-Cyld
D9) mice 72 hours after thioglycollate injection. Data are depicted as mean absolute numbers (6SEM) from n=7
control and 5 M-Cyld
D9 mice at 8 weeks of age. The statistically significant difference in the macrophage populations (Mac1
+ Gr1
2) of control and
mutant mice is depicted by two stars (p,0,001, Student’s unpaired t test).
doi:10.1371/journal.pone.0016397.g002
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similar numbers of cells were recovered from the peritoneal cavity
of control and mutant mice (data not shown). However, at
72 hours after thioglycollate injection, there were significantly
fewer cells recovered from the peritoneal cavity of M-Cyld
D9 mice
compared with control mice (approximately 6 million from
M-Cyld
D9 mice versus more than 20 millions from control mice,






+) were dramatically decreased in M-Cyld
D9 mice in
comparison to control mice (Fig. 5B). Notably, the Cyld
D9
macrophages that were recruited to the inflammatory site
exhibited similar expression pattern of the activation maker F4/
80 (data not shown). At this point it is not clear whether Cyld
D9
macrophages cannot be recruited due to defects in the migration
process itself as a result of microtubule reorganization problems
[19,20] or if they cannot «perceive» the inflammatory stimulus due
to signaling defects. Alternatively it is also possible that the reduced
accumulation of Cyld-deficient macrophages at the site of
inflammation reflects an increased propensity of these cells to
death following their recruitment to the site of inflammation.
Nevertheless, it is undisputable that in the context of chemically
induced aseptic peritonitis Cyld
D9 macrophages are unable to
respond properly.
The development and characterization of M-Cyld
D9 mice
permitted the functional evaluation of CYLD in the myelomono-
cytic lineage and revealed an anti-inflammatory element of the
functional profile of this molecule. Our findings add to a growing
list of evidence that highlight the discrete and in certain cases
contradictory tissue-specific activities of CYLD. For example,
inactivation of CYLD in thymocytes leads to excessive apoptosis
and impaired development [7,11] whereas in peripheral T and B
cells ablation of Cyld expression causes their hyperresponsiveness
which can be associated with spontaneous autoimmune and
inflammatory symptoms [21,22]. The tissue-specific biological
function of CYLD can be associated at least partly, with the
differential role of the transcription factor NF-kB, which is
regulated by CYLD, in different cellular contexts. Taken together
Figure 3. Elevated basal activity of NF-kBi nCyld
D9 BMDMs.
A) EMSA of NF-kB DNA binding activity in BMDMs from control
(M-Cyld
+) and mutant (M-Cyld
D9) mice in the absence or presence of
100-fold excess of unlabeled probe (1006cold probe) as indicated. The
positions of NF-kB-containing complexes of the radiolabeled probe are
shown. B) Immunoblot of nuclear extracts used in A with an anti-TFIIB
antibody. Three mice per genotype were evaluated.
doi:10.1371/journal.pone.0016397.g003
Figure 4. Attenuation of LPS-induced endotoxic shock in
M-Cyld
D9 mice. A) Ten control (4 Cyld
flx9/+ and 6 Cyld
flx9/+ LysMcre)
and eight M-Cyld
D9 mice were subjected to LPS induced endotoxic
shock (32 mg LPS/kg) and survival was monitored for the next 5 days.
M-Cyld
D9 mice exhibited increased resistance to endotoxemia in
comparison to control mice. Data are depicted as mean absolute
numbers (6SEM) from n=10 control and 8 M-Cyld
D9 mice at 8 weeks of
age. (p value=0,02 as assessed by Student’s unpaired t test).
B) Concentrations of TNFa were measured by enzyme-linked immuno-
sorbent assay in supernatants from control and M-Cyld
D9 BMDMs before
and 24 h after treatment with 100 ng/mL LPS. The results shown are
the means (6S.D.) of triplicate measurements. Control BMDMs were
isolated from 3 wild type and 4 Cyld
flx9/+LysMCre mice and M-Cyld
D9
BMDMs were isolated from 4 mice.
doi:10.1371/journal.pone.0016397.g004
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importance of evaluating the functional role of genes by tissue-
specific targeting, in order to clarify possibly contradictory findings
that may stem from the compound effect of a gene’s ablation in
multiple tissues.
In summary, our experiments identified a cell-intrinsic require-
ment of functional CYLD for the efficient response of macro-
phages to different inflammatory stimuli and raise the possibility of
targeting CYLD with inhibitory molecules as a pharmacological
approach to control certain cases of pathogenic inflammation.
Materials and Methods
Ethics statement
Experiments on live animals were approved by the Hellenic
Ministry of Rural Development-(Directorate of Veterinary Ser-
vices, approval ID: 3926) and by Biomedical Sciences Research
Center ‘‘Al. Fleming’s Animal Research and Ethics Committee for
compliance to FELASA regulations (approval ID: 2140).
Mice
The generation of Cyld
flx9]/flx9 mice has been described
elsewhere [9]. Cyld
flx9]/flx9 mice were crossed with LysMcre mice
[10] in order to mutate Cyld in myelomonocytic cells. The mice
were bred and maintained in the animal facilities of the Biome-
dical Sciences Research Centre ‘‘Alexander Fleming’’ under
specific-pathogen free conditions.
BMDM preparation
BMDM were generated as previously described [23].
LPS induced endotoxic shock
Mice of 8 weeks age were intraperitoneally injected with a
sublethal dose of 800 mg LPS (Sigma)/25 g animal weight and
survival was monitored for 5 days.
Electrophoretic mobility shift assay (EMSA)
Nuclear extracts were prepared by BMDMs and EMSA was
performed as previously described [9].
The sequence of the oligonucleotides used for NF-kB with two
tandemly repeated NF-kB binding sites (underlined) were as
follows:
NF-kBf: 59 -ATC AGG GAC TTT CCG CTG GGG ACT
TT- 39
NF-kBr: 59-CGG AAA GTC CCC AGC GGA AAG TCC CT-39
In Vivo migration assay
Control and M-Cyld
D9 mice were injected i.p. with 1 ml of 4%
sterile thioglycollate (Becton Dickinson). 72 h later mice were
sacrificed and the leukocyte number in the peritoneal lavage was
assessed by a Coulter Counter. The percentage of the different cell
types was assessed by Flow Cytometry.
Flow Cytometry and Cell Sorting
Cell-associated fluorescence was analyzed by a FACS Aria or a
FACSCantoII flow cytometer and the DIVA V6 software (Becton
Dickinson). Sorting was performed with BD FACS Vantage SE II.
Flow cytometry figures were prepared using the FlowJo software
(Tree Star, Inc). Differences in populations were determined using
the unpaired t test as calculated with Sigmaplot 9 statistical
software.
ELISA
For the TNFa (provided by W. Buurman, Nutrition and
Toxicology Research Institute Maastricht, Maastricht, Nether-
lands) ELISA assay, BMDMs cultures (3610
5 cells/well)
were incubated with 100 ng/ml LPS (Salmonella enteriditis;
Sigma-Aldrich) and 24 h later the culture supernatants were
collected.
Figure 5. Impaired accumulation of thioglycollate-elicited
peritoneal macrophages in M-Cyld
D9 mice. A) Enumeration of cells
in the peritoneal cavity fluid that was collected from control (M-Cyld
+)
and mutant (M-Cyld
D9) mice 72 hours after thioglycollate injection. Data
are depicted as mean absolute numbers (6SEM) from n=7 control and
7 M-Cyld
D9 mice at 8 weeks of age. The statistically significant difference
in peritoneal cavity cellularity between control and mutant mice is
depicted by two stars (p=0,0000000064, Student’s unpaired t test).





+) from control (M-Cyld
+) and mutant (M-Cyld
D9)
mice as assessed by flow cytometric analysis of cells harvested from the
inflamed peritoneum 72 hours after thioglycollate injection by means
of CD11b and Gr1 expression. Data are depicted as mean absolute
numbers (6SEM) from n=7 control and 7 M-Cyld
D9 mice at 8 weeks of
age. The statistically significant difference in peritoneal cavity cellularity
between control and mutant mice is depicted by two stars (p,0,01
unpaired t test).
doi:10.1371/journal.pone.0016397.g005
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Cells were stained with Ly6c, CD31, CD11b, Gr1, CD16/
32(BD Pharmingen), F4/80 (eBioscience), Lin- enriched fraction
from bone marrow was prepared by staining with biotinylated
Ter119, B220, Cd11b, Gr1, CD3 (eBioscience). Cylindromatosis
and TFIIB were purchased from Santa Cruz. The anti-actin
mouse monoclonal antibody was purchased from MP Biomedical
Inc.
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